Skip to main content
. Author manuscript; available in PMC: 2014 Dec 1.
Published in final edited form as: J Neuroimmune Pharmacol. 2013 Mar 19;8(5):10.1007/s11481-013-9446-8. doi: 10.1007/s11481-013-9446-8

Table 1.

Age, Gender, and Ethnicity of all cases and controls included in the screening study.

Controls (n = 5) Cases: HIV+ (n = 6) Cases: HIV+MA (n = 5)
I.D. Age Gender Ethnic ity I.D. Age Gender Ethnicity HIVVL CD4 I.D. Age Gender Ethnicity HIVVL CD4
CC191 20 M Black CE147† 37 M White 8.8×105 22 CA115 37 M White 2.8×105 23
CA293† 26 M White CC125 38 M White 7.2×104 1 CA248 45 M White 7.8×105 7
CD101 43 M Hispanic CC106† 39 M Hispanic 570 79 CA176† 32 M Hispanic NA 8
CD102† 48 M White CC120† 45 M Black 5.0×104 1 CA186 61 M White 7.2×104 28
CA295† 53 M White CA143 52 M White 165 NA CE156† 35 M Hispanic 3.3×104 0
CG103† 40 M Hispanic 0 53
Mean 38 100%M 3 W
1 B
1 H		 Mean 42 100% M 3 W
1 B
2 H		 1.7(3.3) ×105 53.5 (59.6) Mean 39 100% M 3 W
2 H		 2.3(3.1) ×105 13.8 (10.9)

I.D. - Coded study identifier; HIV VL - blood viral load (copies/mL); CD4 - blood CD4 count per μL; M - Male; W - White, H - Hispanic, B - Black,

†

Paraffin embedded sections for these cases were available for in situ hybridization analysis.